340B omnibus guidance withdrawn

Feb 01, 2017 - 03:30 PM

The administration yesterday withdrew the Health Resources and Services Administration’s pending omnibus guidance for the 340B Drug Pricing Program. “We are pleased that the Administration chose not to finalize the Health Resources and Services Administration’s guidance, which, if enacted would have jeopardized hospitals’ ability to serve vulnerable populations, including low-income and uninsured individuals and patients receiving cancer treatments,” said AHA Executive Vice President Tom Nickels. AHA previously expressed strong concerns regarding HRSA’s proposed policy changes, stating that re-defining 340B patient eligibility would have narrowed inappropriately the number of drugs that qualify for 340B pricing and threatened access to care for patients who need it the most. In addition, AHA objected to HRSA’s proposals regarding infusion services, and urged that patients receiving infusion services provided at 340B hospitals or their outpatient sites be allowed to continue to qualify for 340B drug discount pricing. 

Related News Articles

Headline
CMS launches clinical laboratory fee schedule reporting module for data collection
The Centers for Medicare & Medicaid Services has begun collecting private payor rate data through its Fee-for-Service Data Collection System Clinical Lab…
Headline
Senators introduce AHA-supported bill granting extension of Medicare payment model for rural hospitals
Sens. Chuck Grassley, R-Iowa, and Michael Bennet, D-Colo., April 30 introduced the Rural Community Hospital Demonstration Reauthorization Act, legislation that…
Headline
AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
CMS, FDA announce pathway to expedite access to certain medical devices for Medicare beneficiaries
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Blog
Why Paragon Gets Hospitals Wrong: Report Ignores Reality of Care Delivery
Public
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
DOJ updates Title II web, app nondiscrimination rule timelines for state and local governments; HHS Section 504 rules remain unchanged
As published April 20, the Department of Justice released an interim final rule in the Federal Register to delay compliance dates for states and local…